Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Moderate to Very Severe COPD
NCT02138916Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2014
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL. Started Jun 2014; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02138916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138916.